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Abstract
Background: The incidence of ovarian cancer increases sharply with age, and many elderly
patients have coexisting diseases. If patients with comorbidities are diagnosed with advanced stages,
this would explain the poor survival observed among ovarian cancer patients with severe
comorbidity. Our aims were to examine the prevalence of comorbidity according to stage of
cancer at diagnosis, to estimate the impact of comorbidity on survival, and to examine whether the
impact of comorbidity on survival varies by stage.
Methods: From the Danish Cancer Registry we identified 5,213 patients (> 15 years old) with
ovarian cancer diagnosed from 1995 to 2003. We obtained information on comorbidities from the
Danish National Hospital Discharge Registry. Vital status was determined through linkage to the
Civil Registration System. We estimated the prevalence of comorbidity by stage and computed
absolute survival and relative mortality rate ratios (MRRs) by comorbidity level (Charlson Index
score 0, 1–2, 3+), using patients with Charlson Index score 0 as the reference group. We then
stratified by stage and computed the absolute survival and MRRs according to comorbidity level,
using patients with Charlson score 0 and localized tumour/FIGO I as the reference group. We
adjusted for age and calendar time.
Results: Comorbidity was more common among patients with an advanced stage of cancer. One-
and five-year survival was higher in patients without comorbidity than in patients with registered
comorbidity. After adjustment for age and calendar time, one-year MRRs declined from 1.8 to 1.4
and from 2.7 to 2.0, for patients with Charlson scores 1–2 and 3+, respectively. After adjustment
for stage, the MRRs further declined to 1.3 and 1.8, respectively. Five-year MRRs declined similarly
after adjustment for age, calendar time, and stage. The impact of severe comorbidity on mortality
varied by stage, particularly among patients with tumours with regional spread/FIGO-stages II and
III.
Conclusion: The presence of severe comorbidity was associated with an advanced stage of
ovarian cancer. Mortality was higher among patients with comorbidities and the impact of
comorbidity varied by stage.
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Background
Ovarian cancer is the leading cause of death from gynae-
cological cancer in western countries. It has a poor prog-
nosis, with five-year survival rates ranging from 26% to
51% in Europe [1]. As the incidence of ovarian cancer
increases sharply with age, many patients have one or
more other chronic diseases, i.e., comorbidities [2,3].
Comorbidity is an important predictor of prognosis in
patients with chronic diseases, including cancer [4,5].
Among women with ovarian cancer, the presence of
comorbidity may substantially influence the diagnostic
work-up, alter treatment efficacy, and affect survival.
Few studies to date have examined the impact of comor-
bidity on ovarian cancer survival [6-11]. The presence of
comorbidity at time of diagnosis was found to have a neg-
ative impact on prognosis and survival in two studies
[7,9], but not in others [6,8,10,11]. Based on hospital dis-
charge registry data, we recently reported that one-year
mortality in a Danish regional study was twice as high in
ovarian cancer patients with severe comorbidity as in
those without recorded comorbidity [12]. However, the
study was limited by lack of information on the stage of
cancer and by our inability to exclude patients with bor-
derline tumours.
The presence of comorbidities may influence stage at diag-
nosis, which in turn is a strong predictor of survival in
ovarian cancer patients. It is possible that patients with
comorbidities experience delay in diagnosis, resulting in a
more advanced cancer stage. We thus hypothesized that
poorer survival among ovarian cancer patients with severe
comorbidity, compared with those without comorbid
conditions, may be explained by a higher prevalence of
advanced cancer at diagnosis.
The Danish Cancer Registry records stage information on
incident ovarian cancers. Using data from this Registry, we
conducted a nationwide study to determine the preva-
lence of comorbidity by stage of ovarian cancer, to esti-
mate the impact of comorbidity on survival and mortality,
controlling for cancer stage, and to examine whether the
effect of comorbidity on ovarian cancer mortality varies
by cancer stage at diagnosis.
Methods
We conducted this nationwide study in Denmark, which
has approximately 5.4 million inhabitants, from January
1, 1995 to December 31, 2005. The entire Danish popula-
tion has free access to tax-supported medical care, includ-
ing hospitalization. There is practically no private
inpatient ovarian cancer treatment available. In 2004, sur-
gery for ovarian cancer took place in 52 hospital depart-
ments [13], five of which were gynecologic oncologic
centers. Thus, treatment of this cancer is quite decentral-
ized in the Danish setting.
Identification of ovarian cancer patients
The Danish Cancer Registry
The Danish Cancer Registry has kept records of all patients
in Denmark with malignant neoplasms since 1943 [14].
The cancer stage at the time of diagnosis is reported to the
Danish Cancer Registry as either localized tumour,
tumour with regional spread, tumour with distant metas-
tases or, alternatively, by stage according to the FIGO clas-
sification [15]. For tumours categorized as regional
spread, we were unable to determine whether it was a
FIGO-stage II or FIGO-stage III tumour, therefore we used
the scheme of Kjaerby-Thygesen et al. to categorize ovar-
ian cancer cases into four groups: (a) localized tumours/
FIGO-stage I tumours; (b) tumours with regional spread/
FIGO-stage II and III tumours; (c) tumours with distant
metastases/FIGO-stage IV tumours (also referred to as
"advanced stage" below); and (d) tumours with unspeci-
fied stage [16]. The Cancer Registry provided dichot-
omized data on cancer treatment within the first four
months following diagnosis, such as surgery (yes/no),
chemotherapy (yes/no), radiation (yes/no), and other
(yes/no) [17]. The Registry also contains information on
histological types.
We searched the Danish Cancer Registry for patients with
a first-time ovarian cancer diagnosis [International Classi-
fication of Diseases (ICD), 7th  revision, codes 175.0,
175.1, 175.2, 175.3, 375.0, 475.0, or 875.0] [18] between
1 January, 1995 and 31 December, 2003. We omitted chil-
dren since ovarian cancer seldom occurs in childhood and
often has a different clinical picture than in adults. Eight
patients younger than 15 years thus were excluded from
the analysis.
Data on comorbidity
The Danish Hospital Discharge Registry
The Danish National Hospital Discharge Registry [19]
contains information on all patients discharged from
non-psychiatric hospitals in Denmark since 1977. Data
on outpatient visits have been included since 1995 [20].
Information initially is collected in county-specific hospi-
tal discharge registries immediately upon discharge, and
then is transferred to the National Registry. Data in this
Registry, which covers more than 99% of all non-psychi-
atric discharges nationwide [19], are used routinely to
monitor hospital admissions and discharges, waiting lists,
operations, and treatment. Records include civil registra-
tion number (CPR), dates of admission and discharge,
surgical procedure(s) performed, and up to 20 discharge
diagnoses, which are classified by physicians according to
the Danish version of the International Classification ofBMC Cancer 2008, 8:31 http://www.biomedcentral.com/1471-2407/8/31
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Diseases (ICD) (8th revision until the end of 1993 and
10th revision thereafter) [19].
For each patient with ovarian cancer identified from the
Danish Cancer Registry, we extracted all discharge diag-
noses documented in the Hospital Discharge Registry
between January 1, 1977 and the date of ovarian cancer
diagnosis. We obtained 18 to 26 years of hospitalization
history for each patient, depending on date of diagnosis,
and used this information to compute the Charlson
Comorbidity Index [4]. This Index is a weighted index of
the number and the seriousness of comorbid diseases
[21], which has been widely used in studies of cancer
patients [5,22-25]. Because ovarian cancer defined our
study cohort, we excluded this diagnosis from Index cal-
culations. The comorbid conditions in the 5,213 ovarian
cancer patients are shown in Table 1.
Patients were categorized in three groups according to
their Charlson Index comorbidity score: score 0 (no
recorded comorbidity), score 1–2 (moderate comorbid-
ity), and score 3 or more (severe comorbidity).
Record linkage
Since 1968, a unique 10-digit civil registration number
has been assigned to each Danish resident by the Central
Office of Civil Registration. Use of this number permits
data linkage between registries. The Civil Registration Sys-
tem is updated daily, and contains information on vital
status, date of death, and the residence of all Danish resi-
dents [26]. We used information from this Registry to fol-
low patients until death, emigration, or 31 December
2005, whichever came first, and to compute all-cause
mortality.
Statistical analyses
Stage of cancer associated with comorbidity
We constructed contingency tables of cancer stage and
comorbidity level. Using Mantel-Haenszel methods [27],
we then computed age-adjusted prevalence ratios to com-
pare the prevalence of distant metastases/FIGO IV among
patients with comorbidity with that among patients with-
out comorbidity.
Comorbidity, stage of cancer and survival
We computed Kaplan-Meier survival curves for each
Charlson comorbidity group and cancer stage (localized/
FIGO-stage I tumours, tumours with regional spread/
FIGO-stage II and III tumours, and tumours with distant
metastases/FIGO-stage IV tumours).
Using Cox proportional hazards regression analysis, we
computed one- and five-year crude and adjusted hazard
ratios as a measure of mortality rate ratios [28]. Patients
with no registered comorbidity served as the reference
group. We adjusted first for age and calendar time (3-year
calendar periods) and then for cancer stage.
Design variables were created for the 12 combinations of
stage and comorbidity. For each stratum we computed
one- and five-year survival using Kaplan-Meier product
limit methods [29], absolute survival was defined as the
proportion of the patients who were still alive one- or five-
years after diagnosis. Cox proportional hazards regression
analysis was used to compare mortality rates. Patients
with localized tumours/FIGO-stage I tumours and no reg-
istered comorbidity served as the reference group. We
adjusted for age and year of diagnosis (3-year calendar
periods).
In addition, the analyses were repeated adjusting for treat-
ment. We also conducted analyses restricted to ovarian
cancer patients who had received either surgery, chemo-
therapy or both within the first four months after diagno-
sis.
We verified the assumption of proportional hazards in the
Cox model graphically. Estimates are provided with their
corresponding 95% Confidence Intervals (95% CI). Anal-
yses were performed using STATA version 9.2 (Stata Cor-
poration, College Station, Tx, USA).
Results
Descriptive data
We identified 5,213 patients above 15 years of age diag-
nosed with ovarian cancer from 1995 to 2003. Of these,
3,727 (72%) had no comorbidity recorded in the
Table 1: Comorbid conditions in the 5,213 ovarian cancer 
patients
Conditions Total (%) Charlson score
Myocardial infarct 113 (2.2%) 1
Congestive heart failure 117 (2.2%) 1
Peripheral vascular disease 112 (2.2%) 1
Cerebrovascular disease 229 (4.4%) 1
Dementia 17 (0.3%) 1
Chronic pulmonary disease 232 (4.5%) 1
Connective tissue disease 137 (2.6%) 1
Ulcer disease 180 (3.5%) 1
Mild liver disease 47 (0.9%) 1
Diabetes type 1 or type 2 124 (2.4%) 1
Hemiplegia 8 (0.2%) 2
Moderate or severe renal disease 39 (0.8%) 2
Diabetes with end organ damage type 
1 or type 2
50 (1.0%) 2
Any tumour (not ovarian cancer) 490 (9.4%) 2
Leukemia 9 (0.2%) 2
Lymphoma 13 (0.3%) 2
Moderate or severe liver disease 11 (0.2%) 3
Metastatic solid tumour 160 (3.1%) 6
AIDS 0 6BMC Cancer 2008, 8:31 http://www.biomedcentral.com/1471-2407/8/31
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National Hospital Discharge Registry, 1,116 (21%) had
Charlson score 1–2, and 370 (7%) had Charlson score 3+
(Table 2). The median age was 62 years in patients with-
out comorbidity, 70 years in patients with Charlson score
1–2, and 71 years in patients with Charlson score 3+.
Patients without comorbidity were more frequently
treated with surgery/chemotherapy (47%) than patients
with severe comorbidity (27%) (Table 2).
An association between comorbidity and advanced stage,
for whom information on stage of disease was available,
was found only among patients with severe comorbidity.
The age-adjusted prevalence ratio was 1.0 (95% CI,
0.9–1.1) among patients with moderate comorbidity.
Among patients with severe comorbidity, 42% had distant
metastases/FIGO IV, compared to 28% of patients with-
out comorbidity (age-adjusted prevalence ratio = 1.3,
95% CI, 1.1–1.5).
Comorbidity survival and mortality
Estimates of one- and five-year survival and MRR by level
of comorbidity are shown in Table 3. One- and five-year
survival was higher in patients without comorbidity than
in patients with registered comorbidity. After adjustment
for age and calendar time, one-year MRRs declined from
1.8 to 1.4 for patients with Charlson score 1–2 and from
2.7 to 2.0 for patients with Charlson score 3+. When
adjustment for stage was added to the model, the MRRs
further declined to 1.3 for patients with Charlson score
1–2 and 1.8 for patients with Charlson score 3+. Five-year
MRRs declined similarly after adjusting for age, calendar
time, and stage.
Comorbidity, stage of cancer and survival
Figures 1, 2, 3 show survival curves for patients with ovar-
ian cancer by level of comorbidity at time of diagnosis.
For all stages, survival was higher in patients without
comorbidity than in patients with comorbidity. One- and
five-year survivals are shown in Tables 4 and 5.
For all stages, we found higher crude MRRs among
patients with comorbidity compared with patients with-
out comorbidity. While MRRs declined after adjustment
for age and calendar time, they remained higher among
patients with comorbidity (Tables 4 and 5).
Table 2: Characteristics of ovarian cancer patients, N = 5,213.
Charlson Comorbidity score
Comorbidity 0 Comorbidity 1–2 Comorbidity 3+
Number 3,727 (72%) 1,116 (21%) 370 (7%)
Median age, years 62 70 71
(25% – 75% percentile) (52–72) (59–77) (62–78)
Age groups
< 50 years 726 (19%) 96 (9%) 21 (6%)
50–69 years 1,897 (51%) 474 (42%) 153 (41%)
70–89 years 1,079 (29%) 521 (47%) 188 (51%)
90+ years 25 (< 1%) 25 (2%) 8 (2%)
Year of diagnosis
1995–1997 1,278 (74%) 336 (19%) 119 (7%)
1998–2000 1,300 (71%) 406 (22%) 119 (7%)
2001–2003 1,149 (69%) 374 (23%) 132 (8%)
Extent of cancer
Localized/FIGO I 774 (21%) 184 (16%) 37 (10%)
Regional/FIGO II and III 1,757 (47%) 492 (44%) 157 (42%)
Distant metastases/FIGO IV 1,002 (27%) 338 (30%) 140 (38%)
Unspecified/missing 194 (5%) 102 (9%) 36 (10%)
Histological type
Epithelial 3,422 (92%) 985 (88%) 322 (87%)
Non-epithelial 305 (8%) 131 (12%) 48 (13%)
Treatment
Surgery/Chemotherapy 1,753 (47%) 378 (34%) 101 (27%)
Surgery 1,416 (38%) 442 (40%) 132 (36%)
Chemotherapy 230 (6%) 94 (8%) 32 (9%)
Other* 12 (< 1%) 9 (< 1%) 6 (2%)
No/Symptomatic 285 (8%) 178 (16%) 94 (25%)
Missing 31 (< 1%) 15 (1%) 5 (1%)
*Hormonal treatment, radiation, other not specifiedBMC Cancer 2008, 8:31 http://www.biomedcentral.com/1471-2407/8/31
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We found a varying effect of severe comorbidity on one-
year mortality according to stage of ovarian cancer.
Tumours with regional spread/FIGO stage II and III fur-
ther increased the impact of severe comorbidity on mor-
tality (Table 4). Compared with patients with no
registered comorbidity and localized tumour/FIGO I,
patients with severe comorbidity and this cancer stage had
an adjusted MRR of 2.7, patients with no registered
comorbidity and tumours with regional spread/FIGO
stage II and III had an adjusted MRR of 4.8, and patients
with severe comorbidity and tumours with regional
spread/FIGO stage II and III had an adjusted MRR of 12.3.
Although not as pronounced, a similar variation in the
effect of severe comorbidity by stage was seen in five-year
mortality (Table 5). The impact of moderate comorbidity
on one- and five-year mortality varied only slightly by
stage.
Including treatment in the analysis did not remove the
association between severe comorbidity and mortality
(data not shown), except for tumours with distant metas-
tases/FIGO-stage IV.
Analyses restricted to patients who received either surgery,
chemotherapy or both yielded results similar to analyses
including all ovarian cancer patients (data not shown).
Kaplan-Meier survival curves for ovarian cancer patients with  distant metastases/FIGO stage IV, according to presence of  comorbidity at time of diagnosis Figure 3
Kaplan-Meier survival curves for ovarian cancer patients with 
distant metastases/FIGO stage IV, according to presence of 
comorbidity at time of diagnosis.
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Kaplan-Meier survival curves for ovarian cancer patients with  localized tumour/FIGO stage I, according to presence of  comorbidity at time of diagnosis Figure 1
Kaplan-Meier survival curves for ovarian cancer patients with 
localized tumour/FIGO stage I, according to presence of 
comorbidity at time of diagnosis.
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Table 3: One- and five-year mortality rate ratios (MRRs) by level 
of comorbidity. The corresponding 95% confidence interval is 
given in parentheses.
Charlson Comorbidity score
01 – 23 +
N (%) 3,727 (72%) 1,116 (21%) 370 (7%)
1-year
Survival in % 73 (71–74) 58 (55–60) 44 (39–49)
MRR 1 (ref.) 1.8 (1.6–2.0) 2.7 (2.3–3.1)
Adj. MRR* 1 (ref.) 1.4 (1.2–1.5) 2.0 (1.7–2.3)
Adj. MRR** 1 (ref.) 1.3 (1.2–1.5) 1.8 (1.6–2.1)
5-year
Survival in % 37 (36–39) 24 (21–27) 12 (8–16)
MRR 1 (ref.) 1.5 (1.4–1.6) 2.3 (2.1–2.6)
Adj. MRR* 1 (ref.) 1.3 (1.2–1.4) 1.8 (1.6–2.1)
Adj. MRR** 1 (ref.) 1.2 (1.1–1.4) 1.7 (1.5–1.9)
*Adjusted for age and calendar time.
**Adjusted for age, calendar time and stage.
Kaplan-Meier survival curves for ovarian cancer patients with  regional spread/FIGO stage II and III, according to presence  of comorbidity at time of diagnosis Figure 2
Kaplan-Meier survival curves for ovarian cancer patients with 
regional spread/FIGO stage II and III, according to presence 
of comorbidity at time of diagnosis.
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Table 4: One-year survival and one-year mortality rate ratio (MRR) by level of comorbidity according to the stage of cancer and 
adjusted for age and calendar time.
Charlson Comorbidity score
0 1–2 3+
Localized tumour/FIGO-stage I
Number 774 184 37
Median age, years 56 67 72
Survival in % 95 (93–97) 88 (82–92) 81 (64–91)
Crude MRR 1 (ref.) 2.8 (1.6–4.6) 4.5 (2.0–10.0)
Adj. MRR 1 (ref.) 2.1 (1.2–3.5) 2.7 (1.2–6.2)
Regional spread/FIGO-stage II, III
Number 1,757 492 157
Median age, years 62 68 69
Survival in % 77 (75–79) 63 (59–67) 47 (39–54)
Crude MRR 5.3 (3.8–7.4) 9.2 (6.5–13.2) 16.0 (10.9–23.6)
Adj. MRR 4.8 (3.5–6.8) 7.1 (5.0–10.1) 12.3 (8.3–18.1)
Distant metastases/FIGO-stage IV
Number 1,002 338 140
Median age, years 66 71 71
Survival in % 50 (47–53) 38 (33–44) 34 (27–42)
Crude MRR 14.1 (10.1–19.7) 20.4 (14.4–28.9) 23.4 (16.0–34.2)
Adj. MRR 11.6 (8.3–16.2) 13.9 (9.8–19.8) 15.7 (10.7–23.1)
Unspecified
Number 194 102 36
Median age, years 66 75 71
Survival in % 62 (55–68) 40 (31–50) 33 (19–49)
Crude MRR 10.1 (6.8–15.0) 19.2 (12.8–28.9) 25.0 (15.0–41.8)
Adj. MRR 8.1 (5.5–12.1) 11.2 (7.4–16.8) 15.3 (9.1–25.7)
The reference group was patients with localized tumour/FIGO I and no registered comorbidity. The corresponding 95% confidence interval is given 
in parentheses.
Table 5: Five-year survival and five-year all-cause mortality rate ratio (MRR) by level of comorbidity according to the FIGO-stages and 
adjusted for age and calendar time.
Charlson Comorbidity score
0 1–2 3+
Localized tumour/FIGO-stage I
Survival in % 79 (76–82) 65 (57–72) 50 (32–65)
Crude MRR 1 (ref.) 1.8 (1.4–2.5) 3.2 (2.0–5.3)
Adj. MRR 1 (ref.) 1.6 (1.2–2.1) 2.3 (1.4–3.8)
Regional spread/FIGO-stage II, III
Survival in % 33 (31–36) 21 (17–25) 12 (7–18)
Crude MRR 4.5 (3.8–5.4) 6.7 (5.6–8.1) 10.1 (8.0–12.7)
Adj. MRR 4.4 (3.7–5.2) 5.7 (4.7–6.9) 8.6 (6.8–10.9)
Distant metastases/FIGO-stage IV
Survival in % 12 (10–14) 8 (5–12) 2 (0.4–6)
Crude MRR 9.7 (8.1–11.5) 12.4 (10.2–15.0) 15.9 (12.6–20.0)
Adj. MRR 8.9 (7.5–10.6) 9.7 (8.0–11.8) 12.1 (9.6–15.4)
Unspecified
Survival in % 36 (29–43) 17 (10–26) 14 (5–29)
Crude MRR 5.1 (4.0–6.5) 9.8 (7.5–12.8) 11.8 (8.0–17.5)
Adj. MRR 4.6 (3.6–5.8) 6.8 (5.2–8.9) 8.0 (5.4–12.0)
The reference group was patients with localized tumour/FIGO I and no registered comorbidity. The corresponding 95% confidence interval is given 
in parentheses.BMC Cancer 2008, 8:31 http://www.biomedcentral.com/1471-2407/8/31
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Discussion
In this population-based nationwide study, we found a
higher prevalence of comorbidity in patients with an
advanced stage compared with a less advanced stage of
ovarian cancer. One- and five-year mortality were nearly
twice as high in patients with severe comorbidity com-
pared to those without registered comorbidity, even after
adjustment for stage. Thus the increased prevalence of
more advanced stage did not entirely explain the associa-
tion between greater comorbidity and higher mortality.
We found further that the impact of severe comorbidity
on one- and five-year mortality varied by cancer stage.
Among the strengths of our study were its large size and
Denmark's uniformly organized health care system,
allowing a population-based design with virtually com-
plete follow-up. However, the accuracy of our findings
depends on the quality of cancer registry and hospital dis-
charge data. The Danish Cancer Registry is known to be
more than 95% complete [14], and in a previous study in
which pathology records were used to confirm diagnoses,
we found that ovarian cancer diagnoses were correct in
97% of the cases in the Registry, [30]. This minimal selec-
tion bias should not be related to the presence of comor-
bidity, however, since comorbidity was independently
recorded before the cancer diagnosis.
Cancer staging is based on a combination of pathologic,
operative, and clinical assessments available at the time of
diagnosis. Some misclassification of stage data may occur,
which could result in residual confounding. There may
also have been some inaccuracy in treatment data used in
the study. These data, obtained from the Danish Cancer
Registry, are limited to treatment given within the first
four months following diagnosis; since Registry reporting
forms are often completed in the early period of treatment
planning, they may not reflect actual treatment. If compli-
cations stemming from comorbidity lead to changes in
treatment, this could result in residual confounding.
We used the validated Charlson Comorbidity Index as a
measure of comorbidity. When applied to administrative
data information on comorbidity is based on ICD-codes.
The comorbid diseases may be coded with different accu-
racy in the different administrative registries and misclas-
sifications occur in most registries [31]. The Charlson
index has been shown to have a high specificity [4], but a
more variable sensitivity when compared with diagnoses
abstracted from the medical charts [32]. It is thus possible
that some patients with comorbid conditions may have
been classified erroneously as having Charlson score 0.
Similarly, patients with severe comorbidity may have
been classified erroneously as having Charlson score 1–2.
However, because comorbidity was independently
recorded before the cancer diagnosis, any misclassifica-
tion of comorbid conditions was probably unrelated to
ovarian cancer stage.
Patients with comorbidities may experience a delay in
diagnosis or they may actually be diagnosed earlier
because they have a close relationship with the health care
system. We found that the presence of severe comorbidity
was associated with an advanced stage of ovarian cancer.
If ovarian cancer progresses from Figo-stage I to IV this
could suggest a delay in diagnosis. It has, however, been
suggested that stage I and stage III may be different forms
of the disease [33].
Our findings disagree with a Dutch population-based
study by Mass et al. [6], which was restricted to approxi-
mately 500 patients with FIGO-stage II and III ovarian
cancer. Using a slightly modified Charlson Comorbidity
Index and adjusting for treatment, age, stage, and period
of diagnosis, they concluded that comorbidity did not
influence prognosis. Other cohort studies have had simi-
lar findings [8,10,11]. A Norwegian population-based
cohort study (N = 571) examining the impact of several
possible prognostic factors on survival found that comor-
bidity was a prognostic factor in univariate but not multi-
variate analyses [11]. One reason this study did not find
an association may be its adjustment for residual tumour.
Presence of a residual tumour is related to the aggressive-
ness of surgery and if comorbidity results in less aggressive
surgery, residual tumour may be an intermediate in the
causal pathway from comorbidity to death. In this situa-
tion, adjustment for residual tumour would be inappro-
priate. The effect of comorbidity on mortality may be
mediated to a large degree by higher volume of residual
tumour. A Dutch population-based study (N = 1,116) that
adjusted for age, stage and treatment also did not find an
independent effect of comorbidity on prognosis [10].
Similarly, an American hospital-based study reported an
age-, stage- and symptom stage-adjusted mortality rate
ratio of 1.04 in ovarian cancer patients with comorbidity
compared to those with no comorbidity [8]. Its study pop-
ulation consisted of 137 ovarian cancer patients recruited
during a period of almost 6 years, which could have intro-
duced selection bias [8].
In accordance with our study, a negative impact of comor-
bidity on ovarian cancer mortality was found in an Amer-
ican population-based and in a German cohort study
[7,9]. In these studies the mortality rate ratios were
adjusted for stage, but the impact of stage on survival was
not reported. The current study corroborates the findings
in our recent study [12] on this topic. Our observation of
the impact of comorbidity on mortality also confirm and
extend findings for other groups of cancer patients,
including breast cancer, prostate cancer, colon cancer, and
lung cancer patients [34].BMC Cancer 2008, 8:31 http://www.biomedcentral.com/1471-2407/8/31
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Since stage did not entirely account for the differences in
mortality in our study, other factors may explain the role
of comorbidity as a negative prognostic factor. The pres-
ence of comorbidity in a cancer patient may influence
treatment choices, which in turn affect prognosis and sur-
vival [10,35]. The optimal treatment of patients with ovar-
ian cancer is surgery and chemotherapy, with regimens
depending on stage [36]. In advanced stages it is impor-
tant to optimally debulk the tumour, and while this exten-
sive surgery can be performed safely in patients with
comorbid conditions [3], not all such patients receive this
treatment [6]. It also is possible that following established
treatment guidelines is not the best strategy for patients
with multiple comorbidities [37], either because they can-
not tolerate the adjuvant chemotherapy necessary after
surgery or because the drugs used to treat their comorbid
diseases may interact with those in chemotherapy regi-
mens. As well, the toxicity of chemotherapy may be exac-
erbated by the side effects of the drugs that are used to
treat comorbidities [38]. While we were able to adjust for
treatment using data from the Danish Cancer Registry,
information was lacking on the aggressiveness of the sur-
gery performed or use of modified chemotherapy regi-
mens. Adjustment for treatment in the analyses did not
diminish the impact of severe comorbidity on the one-
year MRR. However, despite adjustment for treatment,
aggressiveness of treatment could vary in the comorbidity
groups, as indicated a Norwegian study [11].
Because our study addressed all-cause rather than cause-
specific mortality, patients could have died from their
comorbidity or other causes not related to ovarian cancer.
This may also explain some of the higher mortality in
patients with comorbidity. However, it is difficult to dis-
tinguish between the contributions to mortality from the
ovarian cancer itself and that from cancer complications
or comorbidities. An example is death from heart-disease
vs. death due to chemotherapy-related aggravation of pre-
existing cardiac problems.
There is a need for clinicians to be aware of the possible
presence of comorbidity in ovarian cancer patients in
order to improve their treatment. Patients with regional
spread/FIGO stage II and III ovarian cancer are a particu-
larly important subgroup in this context.
Conclusion
In this population-based study of ovarian cancer patients,
we found that the presence of severe comorbidity (Charl-
son score 3+) was associated with an advanced stage of
cancer. Mortality was also higher among patients with
comorbidities, but could not be entirely explained by the
cancer stage.
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